


Medtronic Introduces Innovative Device for Elimination of Coronary Thrombus



U.S. Cardiologists introduced to the increased Power and advanced Deliverability of company's pioneering 'Export Advance' Aspiration Catheter

With more than 10 years experience in designing medical equipment destined to remove thrombus from coronary arteries, the market leader Medtronic, Inc. publicised the U.S. launch of the new-generation Export Advance aspiration catheter.

Offering superior power and greater deliverability this U.S. Food and Drug Administration (FDA) approved device features a pre-loaded stylet, defined as a core wire that runs through the middle of the shaft and designed to offer increased kink resistance while the catheter passes through the vasculature to the aspiration site. Equipped with full-wall variable braiding technology, the Export Advance aspiration catheter further optimises performance by providing changing degrees of stiffness to the device's body length, allowing it to benefit from improved pushing power and flexibility during the vasculature navigation process.

Dr. Hoang Thai, associate program director of the interventional cardiology fellowship at the University of Arizona and an associate professor, believes that by introducing the Export Advance aspiration catheter Medtronic has set a new milestone in the manufacturing of manual thrombectomy devices, sharply increasing deliverability and power of these products.

The innovation was awarded the CE (Conformité Européenne) mark last May. Since then it has been launched in a number of international markets as the most recent addition to the company's portfolio of thrombectomy tools, which also features the renowned Export AP aspiration catheter

Vice president and general manager of Medtronic's coronary business Jason Weidman confirms the company continues its pioneering path by setting higher performance standards with the launch of the Export Advance aspiration catheter. He went on to say: "In addition to superior deliverability, our next-generation device offers high-performing aspiration power that physicians have come to expect from Export aspiration catheters, which to date have been used to treat more than one million patients worldwide."

Medtronic collaborates with top scientists, researchers and clinicians, offering the widest selection of pioneering medical technology needed for the surgical and interventional treatment of cardiovascular disease and cardiac arrhythmias. The company aims to supply services and products that deliver clinical and economic value to healthcare providers and consumers worldwide.

Source: Medtronic 21 October 2013

Published on: Tue, 22 Oct 2013